AAC Development and Production

AAC OverviewPlatformQCContact Us

Persistent infections caused by multidrug-resistant bacteria are a major global public health challenge. The rapid development of antimicrobial resistance necessitates new alternative therapies. The development of therapeutic antibodies against bacterial pathogens is progressing rapidly, with promising candidates such as Merck's approved Bezlotoxumab for C. difficile, showcasing the potential for effective infection treatments. Building on this progress, Antibody-Antibiotic Conjugates (AACs) offer a novel approach, leveraging antibodies' high specificity to selectively target bacteria, meanwhile, they exhibit stronger bactericidal activity. Although the development of AACs for bacterial infections is still in its early stages, they hold significant promise as future antimicrobial agents.

What are AACs ?

AACs represent an innovative approach in anti-infective therapy, utilizing highly specific antibodies or peptide carriers to deliver antibiotics precisely to sites of pathogen infection, overcoming the systemic exposure limitations of traditional antibiotics.

Figure 1 illustrates the structural components of an AAC. Figure 1. Structure of AAC. (Cavaco M, et al., 2022)

Antibody-Antibiotic Conjugates (AACs) offer notable core benefits. Firstly, in targeted enhancement, AACs can significantly increase the local drug concentration by 5-10 times, as seen in lung infection models, thereby reducing the effective dose and decreasing the minimum inhibitory concentration (MIC) by 80%-90%. Secondly, AACs excel in resistance management by ensuring precise drug delivery, which minimizes antibiotic misuse and slows the evolution of resistance. Additionally, AACs enhance biofilm penetration efficiency by 3-5 times against biofilm infections like P. aeruginosa and S. aureus. These attributes make AACs a powerful tool in antimicrobial therapy.

Developing AACs presents key challenges, particularly in optimizing pharmacokinetic (PK) and pharmacodynamic (PD) parameters for effective drug release. The choice of linkers, such as acid-cleavable hydrazone or cathepsin B-responsive linkers, is crucial for ensuring precise drug activation within target cells. Conjugation methods, whether chemical or enzymatic, must minimize variability and maintain the stability of AACs. Ensuring site-specific conjugation is essential to achieve the desired therapeutic efficacy, making careful selection and evaluation of the components and their interaction vital for successful AAC development.

Creative Biogene's AAC Development Service

By precisely combining antibodies' targeting capabilities with optimized antibiotic payloads, Creative Biogene has developed a comprehensive suite of technologies for AAC development. Our integrated platform incorporates advanced carrier design, precise linker chemistry, and cutting-edge conjugation technologies to develop next-generation antibacterial therapeutics that maximize efficacy while minimizing systemic exposure.

Technological Platform

Engineered Targeted Carriers

We develop precision-targeted carriers by combining multi-target antibody engineering with high-affinity peptide screening. Using structural biology and computational simulations, we design antibodies against conserved pathogen epitopes with dual-epitope binding strategies for broad-spectrum coverage. Fc segment modifications optimize carrier enrichment at infection sites, while single-domain antibodies enable effective penetration of deep infection environments.

Linker Chemistry & Controlled Release

Our advanced linker technology ensures precise antibiotic delivery through:

Dual-responsive trigger mechanisms that respond to infection microenvironments
Integration of pH-sensitive chemical bonds (hydrazone bonds) with enzyme-responsive peptide sequences (cathepsin B substrates)
Molecular dynamics simulations to optimize linker rigidity, balancing stability with release efficiency
Real-time monitoring via Fluorescence Resonance Energy Transfer (FRET) to ensure linker cleavage kinetics match pathological conditions
Carefully calibrated release profiles that minimize non-specific activation and maximize therapeutic effect

Antibiotic Payload Optimization

We've developed prodrug modification strategies based on metabolic pathway analysis, introducing lipophilic groups for enhanced membrane penetration and self-degrading side chains to bypass efflux pumps. Targeted activation technologies ensure intracellular release, while quantum calculations and molecular docking optimize binding conformations to overcome ineffectiveness against dormant bacteria.

Conjugation Process & Production

Our manufacturing excellence ensures consistent, high-quality conjugates:

Site-specific conjugation technology utilizing microbial transglutaminase (MTGase) or non-natural amino acids (pAzF)
Continuous flow production processes with online mass spectrometry monitoring
Dual molecular sieve purification technology, removing unbound antibiotics and aggregates

Quality Control Systems

1. Critical Quality Attribute (CQA) Analysis

Parameter	Detection Method	Standard
Antibody Binding Activity	SPR/BLI	Comparable to unconjugated antibody
DAR Value	HIC-HPLC	Optimized for efficacy with consistent batch-to-batch reproducibility
Free Antibiotic Residue	UPLC-MS/MS	Minimal residual levels
Linker Cleavage Efficiency	Fluorescent Labeled HPLC	Efficient release under simulated infection conditions
Inhibitory Activity (MIC)	Broth Microdilution	Potent activity against target pathogens

2. Stability Studies

Our comprehensive stability program ensures long-term product integrity under recommended storage conditions, with minimal potency decrease and high purity maintenance over extended periods. Products demonstrate robust stability through multiple freeze-thaw cycles without significant aggregation or activity loss.

Collaborative Development Model

At Creative Biogene, we understand that fighting antimicrobial resistance requires more than just technical expertise – it demands innovation, dedication, and partnership. Our experienced team has successfully supported numerous AAC development programs from concept to clinical trials, consistently delivering solutions that meet the highest quality and regulatory standards. Contact us today to discuss how we can help transform your antibacterial therapeutic vision into reality.

References:

Yu L, Shang Z, Jin Q, et al. Antibody-Antimicrobial Conjugates for Combating Antibiotic Resistance. Adv Healthc Mater. 2023;12(1):e2202207.
Cavaco M, Castanho MARB, Neves V. The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections. Front Microbiol. 2022;13:835677.

Quick Inquiry